It's not a paid ad but I just wanted to let everyone know that if you’re wondering what I use to get my information for my research, it’s largely Koyfin. I use it daily and rely heavily on it to get the necessary information for my reports. If you’re interested in checking it out (I highly recommend it), you can get 20% off your plan if you use my code here.
I thought long and hard about how I was going to share my notes on this company but frankly, the company is not hard to understand from both a problem-solving side and a growing addressable market. Two points I believe can make for a successful outcome, at least from the 50,000ft view.
Key Highlights
A deSPAC left for dead looking to finally inflect its business in the baby (health) care market.
The company is only one of just a few FDA-cleared medical devices allowed to sell with years of runway between it and its nearest competitor.
Strong word of mouth and organic marketing from happy parents (users) create a natural top-of-funnel customer acquisition for the company.
Recent international expansion more than doubles the addressable market.
Current capital structure is not ideal but for heavy dilution to occur, the current price needs to rise significantly.
We are long the company as a small, turnaround investment into the space.
Business Overview
Owlet (OWLT) is a company that sells FDA-approved baby monitors (Dream Sock / Baby Sat) that attach to your infant’s foot and continuously send you information — via phone app — to read and track your infant’s vital signs.
Subscribe to Cedar Grove Capital Management to read the rest.
Become a paying subscriber to get access to this post and other subscriber-only research reports.
UpgradeA subscription gets you:
- 20 - 30 Subscriber-Only Reports per Year
- Small Cap and Below LONG Equity Research
- SHORT Equity, Special Situations, IPO Investment Research
- Earnings Updates, Thematic Research, and Quick Trade Ideas